The honest answers to your GLP-1 questions, all in one place.

The GLP-1 news worth knowing from the past week — ranked by what actually matters, so you can catch up in a minute.

1. 1
   Research

   Novo Nordisk's CagriSema Shows 25 Percent Average Weight Loss in Women in Post-Hoc Analysis

   A post-hoc analysis of Novo Nordisk's Phase 3 REDEFINE 1 trial found that women taking the 2.4 mg dose of CagriSema, a combination of cagrilintide and semaglutide, lost an average of 25 percent of body weight after 68 weeks versus about 3 percent on placebo, among roughly 2,300 women studied. Novo cautioned the figures reflect an idealized scenario in which patients stayed on treatment without interruption and called the results hypothesis-generating; a US FDA decision on CagriSema for weight management is expected in the fourth quarter of 2026.

   CNBCRead the original at CNBC (opens in a new tab)
2. 2
   Regulatory

   FDA Places Import Alert on Chinese Factories After Finding Black Mold at GLP-1 Ingredient Plants

   FDA inspectors documented black mold, significant insect activity, and falsified quality-control records at two Chinese facilities, Chengdu Shengnuo Biopharm and Nanjing Chengong Pharmaceutical, that manufacture semaglutide and tirzepatide active ingredients used in compounded GLP-1 drugs. The FDA placed both companies on an import alert, blocking their products from entering the US; Chengdu Shengnuo has ties to US distributor ChemWerth, and Nanjing Chengong's parent company is partly owned by US drugmaker Amphastar.

   BloombergRead the original at Bloomberg (opens in a new tab)
3. 3
   Market

   Korea's First Homegrown GLP-1 Drug, Hanmi's Eppe, Set to Launch October 29 at Half the Price of Wegovy

   Hanmi Pharmaceutical confirmed, via its CEO at an October 22 Seoul symposium, that Eppe (efpeglenatide), South Korea's first domestically developed GLP-1 obesity drug, will go on sale October 29, about three weeks after its October 7 regulatory approval. The once-weekly injectable will initially be prescribed at select medical institutions, priced at roughly 129,800 won (about $98) for the first month, which is about half the cost of a comparable starting dose of Wegovy or Mounjaro in the Korean market.

   Korea Biomedical ReviewRead the original at Korea Biomedical Review (opens in a new tab)
4. 4
   Research

   Hormone Therapy May Boost Weight Loss From GLP-1 Drugs in Menopausal Women, Mayo Clinic Study Finds

   A Mayo Clinic Florida study of nearly 3,900 women, presented at the Menopause Societys 2026 annual meeting in San Diego (Oct 20-24), found women combining menopausal hormone therapy with semaglutide lost about 11 percent of body weight at one year versus 9.5 percent for semaglutide alone, with a similar pattern seen for tirzepatide. Lead researcher Dr. Regina Castaneda said the findings are observational and that a randomized trial is needed to confirm whether hormone therapy actually drives the added weight loss.

   HealthDayRead the original at HealthDay (opens in a new tab)
5. 5
   Regulatory

   Apothecary Pharma Recalls Compounded Tirzepatide Vials Over Sterility Concerns

   Apothecary Pharma, a North Carolina compounding outsourcing facility, is recalling 22 vials of compounded tirzepatide and one NAD+ vial nationwide after the FDA classified the action as Class II over sterility concerns. The recalled 18 mg/mL tirzepatide vials carry beyond-use dates from October 7 through November 26, 2026, and the recall follows a December 2025 FDA warning letter citing sterile-manufacturing deficiencies at the facility; no illnesses had been reported as of publication.

   Managed Healthcare ExecutiveRead the original at Managed Healthcare Executive (opens in a new tab)